Table 2.
Analysis of PIK3CA mutations in tumors and blood.
| Patient | Sequencing FFPE tumor tissue | ddPCR FFPE tumor tissue | ddPCR pre-surgery plasma |
|---|---|---|---|
| 1 | Wild type | H1047R (9.4%) | H1047R (0.03%) |
| 2 | Wild type | Wild type | Wild type |
| 3 | Wild type | Wild type | Wild type |
| 4 | Wild type | E545K (28.9%) H1047R (6%) |
E545K (0.01%) H1047R (0.02%) |
| 5 | H1047R | H1047R (25.5%) | H1047R (0.02%) |
| 6 | Wild type | Wild type | Wild type |
| 7 | Wild type | Wild type | Wild type |
| 8 | H1047R | H1047R (26%) | H1047R (0.12%) |
| 9 | E545K | E545K (43.7%) | E545K (0.02%) |
| 10 | Wild type | Wild type | Wild type |
| 11 | H1047R | H1047R (13.8%) | H1047R (0.01%) |
| 12 | Wild type | Wild type | Wild type |
| 13 | Wild type | E545K (16.1%) | Wild type |
| 14 | R:Wild type L:Wild type |
Wild type Wild type |
Wild type Wild type |
| 15 | Wild type | Wild type | Wild type |
| 16 | H1047R | H1047R (32.2%) | H1047R (2.99%) |
| 17 | E545K | E545K (55.6%) | E545K (0.07%) |
| 18 | Wild type | Wild type | Wild type |
| 19 | E545K | E545K (20.3%) | E545K (0.01%) |
| 20 | Wild type | Wild type | Wild type |
| 21 | Wild type | Wild type | Wild type |
| 22 | H1047R | H1047R (28.9%) | H1047R (0.02%) |
| 23 | Wild type | Wild type | Wild type |
| 24 | Wild type | Wild type | Wild type |
| 25 | H1047R | H1047R (30.5%) | H1047R (0.01%) |
| 26 | Wild type | Wild type | Wild type |
| 27 | Wild type | Wild type | Wild type |
| 28 | Wild type | H1047R (9.5%) | H1047R (0.02%) |
| 29 | H1047R | H1047R (43.1%) | H1047R (0.01%) |
Tumor and blood samples from twenty-nine early stage breast cancer patients were analyzed for PIK3CA mutations using Sanger sequencing of formalin fixed paraffin embedded tumors (Sequencing FFPE tumor tissue), ddPCR of formalin fixed paraffin embedded tumors (ddPCR FFPE tumor tissue) and pre-surgery plasma DNA (ddPCR pre-surgery plasma). Percentage reflects fractional abundance of mutant PIK3CA (E545K or H1047R) to total PIK3CA DNA.